SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Somatogen (SMTG)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bharat H. Barai who wrote (306)10/21/1997 10:03:00 AM
From: RalphLStevens,MD  Read Replies (1) of 442
 
Here's an interesting squib from this week's Medical Technology Stock Letter:
"We expect them (SMTG) to report on the Phase II trial using Optro in cardio-pulmonary bypass (CPB) patients and the two trials to test its ability to stimulate the production of red blood cells by year-end. The CPB trial is almost certain to be positive, while the other two are much more speculative. However, if they are positive, it would open the very large market for EPO. Amgen sells over $1 billion a year just for kidney dialysis in the United States. Optro might be used instead of EPO, or more likely , in combination. We do not think any of that potential is in the current stock price. The signing of another corporate partnership is also possible at any time."
-Ralph Stevens, MD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News